Eiger BioPharmaceuticals Aktie [WKN DE: A2AF9X / ISIN: US28249U1051]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Eiger BioPharmaceuticals Inc

01.04.24		Metabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedives (Benzinga)
09.11.23		Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
13.09.23		Eiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In Premarket (RTTNews)
12.09.23		Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta (PR Newswire)
05.09.23		Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
14.08.23		Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
29.06.23		Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO (PR Newswire)
28.06.23		Eiger BioPharmaceuticals to Host Business Update Call Tomorrow (PR Newswire)
11.05.23		Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
13.04.23		Eiger BioPharmaceuticals Strengthens Management Team with New Appointments (PR Newswire)
16.03.23		Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (PR Newswire)
08.02.23		New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19 (PR Newswire)
02.01.23		ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR (PR Newswire)
23.12.22		ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
16.12.22		ROSEN, A TOP RANKED LAW FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
10.12.22		EIGR INVESTOR NEWS: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
08.12.22		Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint (PR Newswire)
07.12.22		Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022 (PR Newswire)
03.12.22		ROSEN, NATIONAL TRIAL LAWYERS, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
24.11.22		ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
17.11.22		ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
11.11.22		ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
08.11.22		Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
03.11.22		Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
02.11.22		Ausblick: Eiger BioPharmaceuticals zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
24.10.22		Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3 (PR Newswire)
11.10.22		Eiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference (PR Newswire)
05.10.22		Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback (PR Newswire)
22.09.22		Eiger BioPharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference (PR Newswire)
06.09.22		Eiger: FDA Ready To Consider Any New Data To Support EUA Application For Peginterferon Lambda (RTTNews)
06.09.22		Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application (PR Newswire)
01.09.22		Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences (PR Newswire)
04.08.22		Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
04.08.22		Ausblick: Eiger BioPharmaceuticals präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
28.07.22		Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4 (PR Newswire)
20.07.22		Eiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies (PR Newswire)
18.07.22		Eiger Appoints Senior Human Resources and Organizational Executive Lisa Kelly-Croswell to Board of Directors (PR Newswire)
27.06.22		Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 (PR Newswire)
13.06.22		Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries (PR Newswire)
08.06.22		Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 (PR Newswire)
07.06.22		Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Posit... (PR Newswire)
03.06.22		Eiger BioPharmaceuticals to Present at the Jefferies Global Healthcare Conference (PR Newswire)
20.05.22		Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies (PR Newswire)
10.05.22		Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan (PR Newswire)
05.05.22		Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
30.04.22		Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (PR Newswire)
25.04.22		Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program (PR Newswire)
21.04.22		Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5 (PR Newswire)
18.04.22		Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments (PR Newswire)
17.03.22		Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Solana noch in diesem Jahr bei 300 US-Dollar?

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

BlackRocks Bitcoin-ETF überholt Gold-ETF

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 15:48
Kaufwert:	EUR
	Hinzufügen Speichern